Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

  • Technology appraisal guidance
  • TA321
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the committee

The evidence review group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Fleeman N, Bagust A, Beale S (2014) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation‑positive melanoma: A single technology appraisal.

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). The company/sponsor was also invited to make written submissions. Professional/specialist and patient/carer groups and other consultees had the opportunity to give their expert views and, along with the company/sponsor, also have the opportunity to appeal against the final appraisal determination.

  • Company/sponsor:

    • GlaxoSmithKline

  • Professional/specialist and patient/carer groups:

    • British Association of Dermatologists

    • British Association of Skin Cancer Specialist Nurses

    • British Dermatological Nursing Group

    • Cancer Research UK

    • Melanoma Focus

    • Melanoma UK

    • Royal College of Nursing

    • Royal College of Pathologists

    • Royal College of Physicians

  • Other consultees:

    • Department of Health

    • NHS England

  • Commentator organisations (did not provide written evidence and without the right of appeal):

    • Bristol‑Myers Squibb

    • Department of Health, Social Services and Public Safety for Northern Ireland

    • Healthcare Improvement Scotland

    • Institute of Cancer Research

    • Liverpool Reviews & Implementation Group, University of Liverpool

    • MRC Clinical Trials Unit

    • National Collaborating Centre for Cancer

    • National Institute for Health Research Health Technology Assessment Programme

    • Roche Products

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on dabrafenib by attending the initial committee discussion and providing written evidence to the committee.

  • Dr Pippa Corrie, Consultant and Associate Lecturer in Medical Oncology, nominated by NCRI/RCP/RCR/ACP/JCCO – clinical specialist

  • Gillian Nuttall, Chief Executive Officer, nominated by Melanoma UK – patient expert

  • Sarah Garner, Patient carer, nominated by Melanoma UK – patient expert.

Representatives from the following company/sponsor attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

  • GlaxoSmithKline.